Boc5 may produce metabolic benefits via multiple synergistic mechanisms and may represent an attractive tool for therapeutic intervention of obesity and diabetes, by means of non-peptidic GLP-1R agonism. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.